#  Eyes On: Michalis Georgiou, MD, PhD 

 





March 10, 2026

 

 

***Eyes On** is our new monthly spotlight feature highlighting faculty and staff across Harvard Ophthalmology*

## **Michalis Georgiou, MD, PhD**

### Instructor in Ophthalmology at Harvard Medical School; Member of the Retina Service and IRD Service at Mass Eye and Ear 

   ![Michalis Georgiou](/sites/g/files/omnuum9886/files/styles/hwp_1_1__360x360_scale/public/2026-02/Georgiou%2C%20Michalis.jpg?itok=GvWQAP47) 

 

**1. How does your clinical work shape the questions you bring to your research, or vice versa?**

My research background in retinal phenotyping and clinical trial endpoints has made me more deliberate in how I evaluate patients longitudinally. We need to think carefully about measurable outcomes, imaging biomarkers, and how today’s clinical observations might inform tomorrow’s therapeutic trials. I try to maintain a continuous feedback loop between “bedside and bench.”

**2. Can you tell us about a current or recent project and what excites you most about where it's heading?**

A major focus of my work has been refining structural and functional endpoints in inherited retinal diseases (IRDs). Through multimodal retinal imaging and deep phenotyping, we are working to better characterize disease progression and identify sensitive outcome measures for emerging therapies.

What excites me most is the translational momentum in IRDs right now. As trials of novel therapeutics expand, the field urgently needs robust, clinically meaningful endpoints. I’m particularly energized by the possibility that improved phenotyping and imaging biomarkers will help accelerate trial efficiency and ultimately bring effective treatments to patients sooner.

**3. What's a problem in the field you think is underappreciated or overdue for more attention?**

While the pipeline for gene and molecular therapies is expanding rapidly, we still face significant hurdles in patient selection, longitudinal monitoring, and defining clinically meaningful outcomes—particularly in slowly progressive diseases.

I also think we need continued investment in high-quality natural history data. Without rigorous longitudinal datasets, it becomes difficult to interpret treatment effects or design efficient trials. Strengthening that foundation will be critical as the therapeutic landscape continues to evolve.

**4. What does collaboration look like in your work—are there unexpected partnerships or disciplines you've drawn from?**

Collaboration is central to my work, particularly because IRDs are rare conditions that inherently require large, well-characterized cohorts to generate meaningful insights. Progress in this field depends heavily on multi-institutional collaboration and the integration of diverse expertise.

   ![Michalis Georgiou at Mount Everest Base Camp](/sites/g/files/omnuum9886/files/styles/hwp_1_1__360x360_scale/public/2026-03/Michalis%20Everest.png?itok=nTYDsVwo) 

 

**Mount Everest Base Camp, Nepal, October 2025**During my time in the IRD research ecosystem, I had the privilege of working with over 100 experts across more than 20 institutions. These experiences reinforced how advances in rare retinal diseases rely on coordinated efforts among clinicians, geneticists, imaging scientists, data scientists, and clinical trialists. Moving forward, I see increasingly large, deeply phenotyped consortia as essential to accelerating therapeutic development in IRDs.

**5. What are you looking forward to—in your work or beyond—in the coming year?**

In the coming year, I’m most excited to continue growing as an attending in medical retina and IRDs, while deepening my involvement in translational research that directly impacts patient care.

More broadly, I look forward to expanding collaborative projects, contributing to the development of emerging therapeutics in IRDs and mentoring trainees. Teaching and mentorship have always been deeply meaningful to me, particularly because I have been fortunate to benefit from exceptional mentors throughout my own training. I hope to pay that forward.

My long-term goal is to help bridge rigorous clinical phenotyping with next-generation therapies in a way that meaningfully improves outcomes for patients.

**6. What is something that you enjoy doing outside of your work?**

I enjoy traveling and exploring unique landscapes and cultures— I have visited 100+ countries and counting! Part of my travels include hiking and challenging high-altitude treks. Two of my more recent treks were Cerro Toco, a stratovolcano in the Atacama Desert in Chile, and Mount Everest Base Camp in Nepal.



 

 

 



 

 See also:- [ Faculty ](/news-categories/faculty)
 
 

 Share on:- [     Facebook ](#)
- [     Twitter ](#)
- [     Linkedin ](#)